
AC Immune (ACIU) Stock Forecast & Price Target
AC Immune (ACIU) Analyst Ratings
Bulls say
AC Immune SA is making significant strides in the development of its neurodegenerative disease therapies, particularly through its innovative NLRP3 program, which could attract expanded interest pending positive EVOKE trial results for Alzheimer’s Disease patients. The promising performance of PD active immunotherapy ACI-7104.056, which has shown a 20-fold increase in antibodies against pathogenic variants of alpha-synuclein, along with stabilization of neurofilament light chain levels, suggests a favorable trajectory for future therapeutic efficacy and safety. Furthermore, the anticipated plaque removal data for ACI-24 could serve as a pivotal catalyst, potentially positioning this immunotherapy as a leading option for high-risk, pre-symptomatic Alzheimer's patients.
Bears say
AC Immune SA reported a significant net operating loss of CHF 16.2 million for the recent quarter, indicating ongoing financial challenges as it advances its clinical pipeline. The company also faced a net loss of CHF 70.4 million for the fiscal year 2025, with a basic and diluted earnings per share (EPS) of (0.70), reflecting its struggle to achieve profitability amid extensive research and development expenses. Additionally, the firm confronts inherent industry risks, including potential negative clinical trial results, regulatory uncertainties, and complications in navigating price-sensitive commercial markets.
This aggregate rating is based on analysts' research of AC Immune and is not a guaranteed prediction by Public.com or investment advice.
AC Immune (ACIU) Analyst Forecast & Price Prediction
Start investing in AC Immune (ACIU)
Order type
Buy in
Order amount
Est. shares
0 shares